Dutch Startup Raises €1.7 Million to Bring Hospital-Grade Heart Tests to Your Doctor's Office
Netherlands, Sunday, 10 May 2026.
HeartEye’s revolutionary wireless device can perform a complete 12-channel heart scan in under 60 seconds, potentially transforming how cardiac conditions are detected outside hospitals. The Amsterdam-based company secured funding from prominent tech executives and health investors to accelerate market launch of technology that could save lives through earlier detection while reducing healthcare costs by preventing unnecessary hospital referrals.
Category and Innovation Overview
This development represents a significant advancement in healthtech, specifically in the field of mobile cardiac diagnostics [1]. HeartEye has developed a patented 12-channel mobile ECG recorder that brings hospital-grade cardiac diagnostics closer to patients [1]. The innovation enables early detection of possible cardiac disorders outside traditional hospital settings, representing a breakthrough in preventive cardiology and remote patient monitoring [1]. The device transforms what was previously a time-consuming and complex process requiring trained professionals into a quick, simple procedure that can be performed anywhere [1].
How the Technology Works
HeartEye’s fully wireless ECG recorder is compact and user-friendly, allowing healthcare providers to complete a 12-channel ECG in less than one minute [1]. The device can be operated by general practitioners, assistants, or nurses, making professional cardiac diagnostics accessible outside hospital environments [1]. Once the heart scan is captured, the digital platform enables healthcare providers to share the ECG data with doctors or specialists for support in interpretation and diagnosis [1]. This streamlined process makes it easier to perform high-quality cardiac diagnostics in GP practices and nursing homes, with plans to eventually enable patients to conduct tests at home [1].
Company Leadership and Investment Details
HeartEye successfully raised €1,675,000 in funding, with the investment round led by ROM InWest [1]. The funding includes participation from notable tech industry veterans, including Schuberg Philis co-founder Pim Berger and Mphasis co-founder Jeroen Tas, alongside returning investor Health Innovations [1]. The company recently strengthened its strategic direction by announcing the formation of its Advisory Board on May 5, 2026, which includes these same investors in advisory roles [2]. The Advisory Board also features Hans van Snellenberg, former MD of Hartwig Medical Foundation, Sara Schaafsma from ROM InWest, and Dick Sietses from Health Innovations [2].
Benefits and Market Impact
The technology addresses critical healthcare challenges by enabling earlier detection of heart problems, ensuring patients reach cardiologists when necessary while preventing unnecessary hospital referrals [1]. This dual benefit contributes to more efficient care delivery, lower costs, and reduced workload pressure on healthcare systems [1]. HeartEye aims to lower cardiovascular mortality by bringing diagnostics out of hospitals and directly to patients [2]. The company is currently approaching CE certification and welcoming its first pre-orders as it prepares for market rollout [2]. The funding will support HeartEye through the capital-intensive certification phase, including conducting pivotal clinical studies and advancing AI software development, while building production capacity to meet expected demand after market approval [1].